Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant.

Filip IonescuJerel C DavidApoorva RavichandranDavid A SallmanKendra SweetRami S KomrokjiOnyee ChanAndrew KuykendallEric PadronRawan FaramandNelli BejanyanFarhad KhimaniHany ElmariahJoseph PidalaAsmita MishraLia PerezTaiga NishihoriJeffrey E Lancet

Published in: Clinical lymphoma, myeloma & leukemia (2024)

These data support the efficacy of this combination in the alloHCT relapse setting where we report responses among nearly half of patients, with possibly greater benefit for NPM1 and IDH 1/2-mutated cases. These responses can be durable and profound as evidenced by conversion to MRD negativity.

Keyphrases

acute myeloid leukemia
hematopoietic stem cell
allogeneic hematopoietic stem cell transplantation
wild type
intellectual disability
low grade
acute lymphoblastic leukemia
big data
multiple myeloma
chronic lymphocytic leukemia
free survival
autism spectrum disorder
machine learning
deep learning
data analysis